Cord Blood for Cerebral Palsy: Clinical Trials and Current Evidence
Cerebral palsy is one of the most actively studied areas in autologous cord blood research, particularly at Duke and a handful of international centers. The evidence base is more mature than autism but still falls short of FDA-approved therapy.
What the trials have shown
Multiple early-phase trials, including work led by Dr. Joanne Kurtzberg at Duke, have given children with cerebral palsy infusions of their own banked cord blood. A 2017 Duke trial reported dose-dependent improvements in motor function on the Gross Motor Function Measure at one year, with higher-dose infusions outperforming lower doses. The effect was modest but statistically significant.
What's still missing
Larger, longer randomized controlled trials are needed to confirm benefit, characterize which subgroups of children benefit most, and establish optimal dosing. Studies of allogeneic (donor) cord blood are also underway. As of 2025, autologous cord blood infusion is not FDA-approved for cerebral palsy — it is studied within clinical trials and a small number of approved expanded-access programs.
Why dose matters — and the banking implication
The Duke data suggested doses around 25 million nucleated cells per kilogram or higher correlated with benefit. For a 30 kg child, that's roughly 750 million cells — at or above the typical content of a single privately banked unit. This is part of why collection volume and cell count matter even for non-transplant uses.
If you have a child with cerebral palsy
- Talk to your child's neurologist about current clinical trials
- Duke's Marcus Center for Cellular Cures maintains an expanded-access program
- If you privately banked at this child's birth, ask whether your unit's cell count meets dosing thresholds
- Be skeptical of cash-pay clinics offering 'stem cell therapy' outside formal trials